HC010 combined with chemotherapy for advanced lung cancer — Phase Ib dosing and safety

Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy Study of the Combination Therapy With HC010 for Injection in Patients With Advanced Solid Tumors:A Multicenter, Open-Label, Dose Range-Finding and Multiple Cohort Dose Expansion Phase Ib Clinical Trial-Lung Cancer Population

This trial tests whether adding HC010 to standard chemotherapy is safe and finds the best dose in people with advanced lung cancer while looking for early signs it helps.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 328 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: HC Biopharma Inc. (Industry-sponsored)
• Drugs / interventions: immunotherapy, chemotherapy
• Locations: 1 site (Guangzhou, Guangdong)
• Trial ID: NCT07381829 on ClinicalTrials.gov

What this trial studies

This multicenter, open-label Phase Ib trial uses a dose‑range finding stage followed by multiple cohort dose expansion to test HC010 in combination with several chemotherapy regimens in patients with advanced lung cancer. Primary goals are to determine tolerability, safety, pharmacokinetics and the recommended dose for later studies, with preliminary efficacy measured by tumor response using RECIST v1.1. Eligible cohorts include broad advanced solid tumors in the range‑finding stage and specific lung cancer populations in expansion (NSCLC subgroups including EGFR‑mutant disease after EGFR‑TKI, driver‑negative first‑line NSCLC, and extensive‑stage SCLC first‑line). Treatment arms combine HC010 with chemotherapy agents such as paclitaxel, pemetrexed, etoposide, or carboplatin/cisplatin under an open‑label design.

Who should consider this trial

Good fit: Ideal candidates are adults with locally recurrent or metastatic unresectable advanced lung cancer with at least one measurable lesion by RECIST v1.1, ECOG performance status 0–1, and who meet the subgroup criteria for the expansion cohorts such as NSCLC after EGFR‑TKI progression or first‑line driver‑negative NSCLC and extensive SCLC.

Not a fit: Patients with only brain lesions as target lesions, those with ECOG >1, or those with earlier‑stage disease are unlikely to be eligible and therefore unlikely to benefit from participation in this trial.

Why it matters

Potential benefit: If successful, the combination could provide a new treatment option or improve response for some patients with advanced lung cancer who have limited standard options.

How similar studies have performed: Combining novel agents with standard chemotherapy has shown benefit in some lung cancer settings, but HC010 appears to be a novel agent with limited published clinical data to date.

Eligibility criteria

Inclusion Criteria:

* 1\. Fully understand this trial and voluntarily sign the informed consent form.
* 2\. For locally recurrent or metastatic non-resectable advanced solid tumors that are diagnosed by histological or cytopathological pathology and cannot be radically treated with radiotherapy, the range-finding stage does not limit specific tumor types and previous treatment conditions, while the dose-expansion stage is limited to NSCLC without standard of care, NSCLC with EGFR-sensitive mutations and progressing after adequate EGFR-TKI therapy. First-line population with driver gene negative non-small cell lung cancer and first-line population with extensive small cell lung cancer.
* 3\. At least one measurable lesion according to RECIST v1.1 (patients with only brain lesion as target lesion are not accepted).
* 4\. Eastern Cancer Assistance Group (ECOG) in the United States had a performance score of 0 or 1 and did not worsen within 2 weeks prior to the first dose.
* 5\. The expected survival time is more than 3 months.
* 6\. Adequate organ and bone marrow function.
* 7\. Females of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose of the investigational drug and be non-lactating; Eligible patients of childbearing potential (male and female) must agree to use a reliable method of contraception (hormonal or barrier method or abstinence) with their partner for at least 6 months from signing informed consent until after the last dose of study drug. Women of non-childbearing potential may not undergo pregnancy test and contraception (postmenopausal for at least 1 year or surgically sterilized).

Exclusion Criteria:

* 1\. Imaging shows that the tumor invades great vessels or is not clearly demarcated from blood vessels.
* 2\. Combination of brain metastasis, meningeal metastasis and spinal cord compression.
* 3\. Prior concurrent anti-programmed death receptor 1 (PD-1)/programmed death ligand (PD-L1), anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), and anti-vascular endothelial growth factor (VEGF) target drugs.
* 4\. Anti-tumor therapy such as radiotherapy, biological therapy, endocrine therapy, targeted therapy and immunotherapy within 4 weeks prior to the first dose of study drug.
* 5\. Concomitant diseases or conditions that may significantly affect the autoimmune status, such as known or suspected active autoimmune system disease, congenital or acquired immunodeficiency, hematopoietic stem cell transplantation or organ transplantation (except keratoplasty), use of live vaccine or attenuated live vaccine within 4 weeks, and use of systemic corticosteroids and immunomodulatory drugs within 2 weeks.
* 6\. Concurrent with severe, uncontrolled and unrecovered acute and chronic diseases, such as acute coronary syndrome, uncontrolled hypertension, serious or poorly controlled diabetes, interstitial pneumonia requiring hormone therapy, severe bleeding tendency or coagulation disorders within the first 6 months.
* 7\. Subjects with other malignant tumors within 5 years before the first dose of study drug.
* 8\. Subjects who have undergone major organ surgery (excluding aspiration biopsy) within 4 weeks prior to the first dose of study drug, or have experienced significant trauma, or require elective surgery during the trial.
* 9\. Adverse reactions from previous anti-tumor treatment have not recovered to NCI-CTCAE Grade 5.0 or below.
* 10\. Subjects with known hypersensitivity to other monoclonal antibodies and allergies to any preparation component of the investigational drug to be used.
* 11\. Subjects with known or suspected immune-related toxicity requiring permanent discontinuation after receiving any previous immunocheckpoint inhibitor therapy.
* 12\. Patients who have received prior anti-angiogenic therapy and experienced Grade ≥3 toxicity associated with anti-angiogenic therapy.
* 13\. The investigator believes that the subject is not suitable to participate in this clinical study for other reasons.

Where this trial is running

Guangzhou, Guangdong

• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)

Study contacts

• Study coordinator: QiQi huang Huang, master

Conditions Advanced Solid Tumor Cancer